Curis Announces Collaborator Roche's Submission of Erivedge for Registration With Australian Regulatory Authority

Curis, Inc. CRIS today announced that its collaborator Roche has submitted an application for marketing registration for Erivedge™ (vismodegib) to Australia's Therapeutic Goods Administration. The application is currently under review by the TGA for the treatment of adults with advanced basal cell carcinoma (BCC) for whom surgery is inappropriate. Erivedge is a first-in-class oral medicine designed to selectively inhibit signaling in the Hedgehog pathway and is being developed by Roche and Genentech, under a collaboration agreement between Curis and Genentech, a member of the Roche Group.